Preliminary Findings From the Phase 2 EPPIK Study of Sparsentan in Pediatric Patients With Selected Proteinuric Glomerular Diseases

## Howard Trachtman<sup>1</sup>, Rosanna Coppo<sup>2</sup>, Ping He<sup>3,\*</sup>, Kenneth V. Lieberman<sup>4</sup>, Alex Mercer<sup>5</sup>, Michelle Rheault<sup>6</sup>, Moin A. Saleem<sup>7</sup>, Teresa Shafer<sup>3</sup>, Radko Komers<sup>3</sup>

<sup>1</sup>University of Michigan, Ann Arbor, MI, USA; <sup>2</sup>Fondazione Ricerca Molinette, Regina Margherita Hospital, Turin, Italy; <sup>3</sup>Travere Therapeutics, Inc., San Diego, CA, USA; <sup>4</sup>Joseph M. Sanzari Children's Hospital of the Hackensack Meridian Health Network, Hackensack, NJ, USA; <sup>5</sup>JAMCO Pharma Consulting, Stockholm, Sweden; <sup>6</sup>University of Minnesota Medical School, Minneapolis, MN, USA; <sup>7</sup>University of Bristol and Bristol Royal Hospital for Children, Bristol, UK \*At the time of the study. To obtain a PDF of this presentation:



Scan the QR code. Charges may apply. No personal information is stored.




Kenneth V. Lieberman; kennethlieberman@hmhn.org Howard Trachtman; howardtrachtman21@gmail.com

Contact information:

Presented at the American Society of Nephrology (ASN) Kidney Week 2023; November 1-5, 2023; Philadelphia, PA, USA

- HT has received consulting fees from Aclipse, Boehringer Ingelheim, Maze Therapeutics, Natera, Otsuka, PhaseV, Travere Therapeutics, Inc., and Walden; received speaking honoraria from the National Kidney Foundation; and participated on data safety monitoring or advisory boards for ChemoCentryx, Otsuka, and Travere Therapeutics, Inc.
- RC has received consultancy fees from Alnylam, Amgen, argenx, Bayer, Calliditas, Chinook, Menarini, Novartis, Purespring, Otsuka-Visterra, Reata, STADApharm, and Travere Therapeutics, Inc.
- **PH** was an employee of Travere Therapeutics, Inc. at the time of the study
- KVL has received consultancy fees and speaker's honoraria from Alexion Pharmaceuticals and Calliditas
- **AM** is an employee of Travere Therapeutics, Inc. and JAMCO Pharma Consulting and has received consultancy fees from HI-Bio, Travere Therapeutics, Inc., and Vera Therapeutics
- MR has received consultancy fees from ENYO Pharma, Visterra, and Walden Biosciences; research funding from Akebia Therapeutics, Chinook Therapeutics, the Department of Defense, NIDDK, Reata Pharmaceuticals, River 3 Renal, and Sanofi; and participated on data safety monitoring/advisory boards for Advicenne
- **MAS** has received consultancy fees and speaker's honoraria from Travere Therapeutics, Inc., Purespring Therapeutics, and ProteinQure
- **TS** is an employee of and owns stock or stock options in Travere Therapeutics, Inc.
- **RK** is an employee of Travere Therapeutics, Inc.

 Sparsentan is a novel dual endothelin angiotensin receptor antagonist (DEARA) approved to treat adults with immunoglobulin A (IgA) nephropathy in the US<sup>1,2</sup> and in development for focal segmental glomerulosclerosis (FSGS).<sup>3,4</sup> Phase 3 trials are PROTECT and DUPLEX




- Dual ET<sub>A</sub> and AT<sub>1</sub> receptor antagonism has anti-inflammatory, antiproliferative, and antifibrotic actions of therapeutic potential in addition to hemodynamic benefits
- The ongoing phase 2 open-label EPPIK (Evaluating Problematic Proteinuria in Kids; NCT05003986) study is examining an oral suspension formulation of sparsentan in pediatric patients with:
  - FSGS
  - Minimal change disease (MCD)
- IgA nephropathy (IgAN)
- IgA vasculitis nephritis (IgAVN)
- Alport syndrome (AS)

## **Objective:** To assess the preliminary efficacy, safety, and tolerability of the oral suspension formulation of sparsentan after 12 weeks of treatment in the EPPIK study

1. Heerspink H, et al. *Lancet.* 2023;401:1584–1594. 2. Rovin BH, et al. *Lancet.* Published online November 3, 2023. 3. Rheault MN, et al. *N Engl J Med.* Published online November 3, 2023. 4. Trachtman H, et al. *J Am Soc Nephrol.* 2018;29(11):2745-2754.




• Open-label, single-arm, descriptive, multicenter trial enrolling  $\approx$  57 pediatric patients




## Baseline characteristics of the 23 patients who had received ≥1 dose of sparsentan at data cutoff (April 5, 2023)

Characteristic	Population 1: MCD or FSGS (n=13)	Population 2: IgAN or AS (n=10)	Total (N=23)
Diagnosis n (%)			
MCD	8 (61.5)	0	8 (34.8)
FSGS	5 (38.5)	0	5 (21.7)
IgAN	0	3 (30.0)	3 (13.0)
AS	0	7 (70.0)	7 (30.4)
IgAVN	0	0	0
Male sex, n (%)	8 (61.5)	8 (80.0)	16 (69.6)
Age, median (IQR), years*	8 (6-13)	13 (12-14)	12 (7-14)
White race, n (%)	12 (92.3)	6 (60.0)	18 (78.3)
UPCR, median (IQR), g/g	3.0 (2.5-5.7)	2.5 (2.1-3.2)	2.8 (2.3-5.0)
Nephrotic-range proteinuria (UPCR ≥2 g/g), n (%)	12 (92.3)	8 (80.0)	20 (87.0)
eGFR, mean (SD), mL/min/1.73 m <sup>2</sup>	106.1 (50.0)	87.3 (27.4)	97.9 (42.0)
Immunosuppressant use at baseline, n(%)	8 (61.5)	1 (10.0)	9 (39.1)
Blood pressure, systolic/diastolic, mean (SD), mm Hg	115.0 (16.1)/69.3 (11.3)	116.2 (10.0)/69.1 (8.4)	115.5 (13.5)/69.2 (9.9)

• Proteinuria decreased from baseline over 12 weeks of sparsentan treatment




• eGFR was broadly stable during the first 12 weeks of treatment



eGFR determined using the modified Schwartz formula. $^{1,2}$ 

1. Schwartz GJ, et al. J Am Soc Nephrol. 2009;20(3):629-637. 2. Schwartz GJ, et al. Clin J Am Soc Nephrol. 2009;4(11):1832-1843.

• Effect of sparsentan on blood pressure during the first 12 weeks of treatment



- Sparsentan was generally well tolerated over the 12-week treatment period
- 1 patient discontinued study treatment due to worsening of nephrotic syndrome

Patients, n (%)	FSGS or MCD population 1 (n=13)	IgAN or AS: population 2 (n=10)	Total (N=23)
Any treatment-emergent adverse event (TEAE)	11 (85)	7 (70)	18 (78)
Most common TEAEs $(\geq 3 \text{ patients in either population})$			
Pyrexia	3 (23)	1 (10)	4 (17)
Vomiting	3 (23)	1 (10)	4 (17)
Headache	3 (23)	1 (10)	4 (17)
Blood creatinine increase	3 (23)	-	3 (13)
Any serious TEAE	4 (31)	2 (20)	6 (26)
Acute kidney injury	0	1 (10.0)	1 (4.0)
Nephrotic syndrome	1 (8.0)	0	1 (4.0)
Hypotension	1 (8.0)	0	1 (4.0)
Fluid retention	1 (8.0)	0	1 (4.0)

Occurrences of other TEAEs such as edema, aspartate aminotransferase increase, fluid retention, hyperkalemia, and hypotension each occurred in 1 patient only

In pediatric patients with a range of proteinuric glomerular diseases, sparsentan treatment resulted in proteinuria reductions over the initial 12 weeks

Sparsentan had a safety profile consistent with that observed in studies of adults with IgAN or FSGS,<sup>1-4</sup> and the oral suspension formulation was generally well tolerated



Enrollment for the EPPIK trial (NCT05003986) is ongoing, and further follow-up over the full study period will evaluate the long-term efficacy and safety, as well as pharmacokinetics and palatability, in children with rare proteinuric glomerular diseases  This study is funded by Travere Therapeutics, Inc. We thank the patients, their families and caregivers, the investigators, and study site staff who are participating in this study. We also thank Nuhira Masthan of Travere Therapeutics for biostatistical support. Medical writing support was provided by Chloe Hayes, BSc, and Nazneen Qureshi, PhD, of Medical Expressions, and was funded by Travere Therapeutics, Inc

## **Questions?**

